DK0504363T4 - Rensede IgG antistoffer - Google Patents

Rensede IgG antistoffer

Info

Publication number
DK0504363T4
DK0504363T4 DK91917891T DK91917891T DK0504363T4 DK 0504363 T4 DK0504363 T4 DK 0504363T4 DK 91917891 T DK91917891 T DK 91917891T DK 91917891 T DK91917891 T DK 91917891T DK 0504363 T4 DK0504363 T4 DK 0504363T4
Authority
DK
Denmark
Prior art keywords
antibody
column
prepn
cdw52
purified
Prior art date
Application number
DK91917891T
Other languages
English (en)
Other versions
DK0504363T3 (da
Inventor
Paul Ian Nicholas Ramage
Geoffrey Langley Court Allen
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0504363(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0504363T3 publication Critical patent/DK0504363T3/da
Publication of DK0504363T4 publication Critical patent/DK0504363T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
DK91917891T 1990-10-17 1991-10-17 Rensede IgG antistoffer DK0504363T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
PCT/GB1991/001816 WO1992007084A1 (en) 1990-10-17 1991-10-17 Purified cdw52-specific antibodies

Publications (2)

Publication Number Publication Date
DK0504363T3 DK0504363T3 (da) 1998-09-21
DK0504363T4 true DK0504363T4 (da) 2007-05-29

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91917891T DK0504363T4 (da) 1990-10-17 1991-10-17 Rensede IgG antistoffer

Country Status (29)

Country Link
US (1) US5644036A (da)
EP (1) EP0504363B2 (da)
JP (1) JP2638680B2 (da)
KR (2) KR960015399B1 (da)
AT (2) ATA900791A (da)
AU (3) AU658926B2 (da)
BE (1) BE1004226A5 (da)
BR (1) BR1100358A (da)
CA (1) CA2069481C (da)
CH (2) CH681455A5 (da)
DE (1) DE69128774T3 (da)
DK (1) DK0504363T4 (da)
ES (2) ES2112865T5 (da)
FI (2) FI110003B (da)
FR (2) FR2668164A1 (da)
GB (2) GB9022547D0 (da)
GR (3) GR910100425A (da)
HU (1) HUT64601A (da)
IE (1) IE913560A1 (da)
IL (3) IL102726A (da)
IT (1) IT1250064B (da)
LU (1) LU88122A1 (da)
MX (1) MX9203794A (da)
MY (2) MY136210A (da)
NZ (2) NZ244114A (da)
PT (2) PT99248B (da)
TW (1) TW283710B (da)
WO (1) WO1992007084A1 (da)
ZA (2) ZA918259B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
CA2120911A1 (en) * 1991-10-15 1993-04-29 Geoffrey Hale Medicaments
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
AU709584B2 (en) † 1995-08-01 1999-09-02 Pasteur Merieux Serums Et Vaccins Industrial production process for a vaccine against Japanese encephalitis, and vaccine obtained
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU228630B1 (en) * 1996-02-09 2013-04-29 Abbott Biotech Ltd Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
JP4391086B2 (ja) 2001-03-09 2009-12-24 中外製薬株式会社 タンパク質精製方法
ES2321539T3 (es) * 2001-06-05 2009-06-08 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
JP5525118B2 (ja) 2002-09-11 2014-06-18 中外製薬株式会社 タンパク質精製方法
CA2502414A1 (en) 2002-10-15 2004-04-29 Intercell Ag Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
PL1869065T3 (pl) 2005-03-11 2020-09-21 Wyeth Llc Sposób prowadzenia chromatografii podziałowej ze słabym wiązaniem
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP3345620A1 (en) 2009-05-13 2018-07-11 Genzyme Corporation Methods and compositions for treating lupus
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
EP3266793A1 (en) 2010-06-21 2018-01-10 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MY181081A (en) 2013-12-27 2020-12-17 Chugai Pharmaceutical Co Ltd Method for purifying antibody having low isoelectric point
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
MX2019000898A (es) 2016-07-25 2019-07-01 Cephalon Inc Amortiguador de lavado de cromatografia de afinidad.
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
WO2020203718A1 (ja) 2019-03-29 2020-10-08 旭化成メディカル株式会社 タンパク質の精製方法
US20220212167A1 (en) 2019-04-08 2022-07-07 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
AU2020273072A1 (en) 2019-04-10 2021-12-09 Chugai Seiyaku Kabushiki Kaisha Method for purifying Fc region-modified antibody
EP4353735A1 (en) 2021-06-10 2024-04-17 Mitsubishi Chemical Corporation Synthetic adsorbent, antibody purification method, and antibody production method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
ATE95068T1 (de) * 1988-02-12 1993-10-15 British Tech Group Modifizierte antikoerper.

Also Published As

Publication number Publication date
ZA926191B (en) 1993-04-16
PT99248A (pt) 1993-06-30
JP2638680B2 (ja) 1997-08-06
ATA900791A (de) 1996-06-15
FI922824A0 (fi) 1992-06-17
IT1250064B (it) 1995-03-30
AU716402B2 (en) 2000-02-24
ES2112865T5 (es) 2007-09-16
US5644036A (en) 1997-07-01
CH681455A5 (da) 1993-03-31
GR3026588T3 (en) 1998-07-31
ES2112865T3 (es) 1998-04-16
FI110002B (fi) 2002-11-15
ATE162552T1 (de) 1998-02-15
AU2532192A (en) 1993-02-11
AU4521897A (en) 1998-02-12
BR1100358A (pt) 2000-03-28
KR920703108A (ko) 1992-12-17
ES2081742B1 (es) 1996-10-01
ES2081742A1 (es) 1996-03-01
GB9022547D0 (en) 1990-11-28
DE69128774T2 (de) 1998-06-04
FR2677997A1 (fr) 1992-12-24
KR100193314B1 (ko) 1999-06-15
FI922824A (fi) 1992-06-17
ITRM910788A0 (it) 1991-10-16
LU88122A1 (fr) 1993-03-15
FI110003B (fi) 2002-11-15
HU9202000D0 (en) 1992-10-28
ITRM910788A1 (it) 1993-04-16
NZ244114A (en) 1995-06-27
GB9209529D0 (en) 1992-07-01
PT99248B (pt) 1999-04-30
MY136210A (en) 2008-08-29
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
EP0504363B1 (en) 1998-01-21
GR920100471A (el) 1994-06-30
AU649078B2 (en) 1994-05-12
CH681305A5 (da) 1993-02-26
IL102726A0 (en) 1993-01-31
HUT64601A (en) 1994-01-28
GB2253397A (en) 1992-09-09
EP0504363A1 (en) 1992-09-23
IL99761A0 (en) 1992-08-18
FR2668164B1 (da) 1995-04-14
GR910100425A (el) 1992-09-25
MY119030A (en) 2005-03-31
CA2069481C (en) 2003-07-29
FI922380A0 (fi) 1992-05-25
DE69128774D1 (de) 1998-02-26
PT100988A (pt) 1994-02-28
EP0504363B2 (en) 2007-02-07
IE913560A1 (en) 1992-04-22
JPH05504579A (ja) 1993-07-15
CA2069481A1 (en) 1992-04-18
NZ240247A (en) 1994-03-25
FR2668164A1 (fr) 1992-04-24
ZA918259B (en) 1993-04-16
WO1992007084A1 (en) 1992-04-30
BE1004226A5 (fr) 1992-10-13
AU7024294A (en) 1995-01-05
TW283710B (da) 1996-08-21
IL102726A (en) 2002-08-14
DK0504363T3 (da) 1998-09-21
KR960015399B1 (ko) 1996-11-13
PT100988B (pt) 1999-08-31
AU658926B2 (en) 1995-05-04
FI922380A (fi) 1992-05-25
MX9203794A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
DK0504363T4 (da) Rensede IgG antistoffer
MX9603637A (es) Purificacion de anticuerpo.
EP0185034A4 (da)
AU7067287A (en) Method and apparatus for separating proteins
Dimitrijevic et al. Purification and characterization of an estrogen-binding peroxidase from human fetuses
SE8902230D0 (sv) Interferon purification process
FR2411202A1 (fr) Procede d'extraction et de purification de la globuline transporteur d'hormones thyroidiennes tbg